BI
IOVA icon

Binnacle Investments’s Iovance Biotherapeutics IOVA Stock Holding History

Binnacle Investments’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$82 Buy
+38
New +$90 ﹤0.01% 927
2025
Q2 		– Sell
-38
Closed -$127 – 818
2025
Q1 		$127 Buy
+38
New +$196 ﹤0.01% 773

Other funds holding IOVA

MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Binnacle Investments's IOVA Position: Q3 2025 in Review

Binnacle Investments opened a new position in Iovance Biotherapeutics (IOVA) in Q3 2025: 38 shares worth $82. The stake represents ﹤0.01% of the portfolio and ranks #927 among its holdings. This is a return to the name: Binnacle Investments previously reported a position in IOVA as recently as Q1 2025.

Binnacle Investments first reported a position in IOVA in Q1 2025 and has held it in 2 quarters since. The position peaked at $127 in Q1 2025. 253 funds tracked by Wall St. Rank hold IOVA as of Q3 2025.

  • Binnacle Investments held 38 shares of Iovance Biotherapeutics worth $82 as of Q3 2025.
  • Iovance Biotherapeutics was a new Binnacle Investments position in Q3 2025.
  • Iovance Biotherapeutics made up ﹤0.01% of Binnacle Investments's portfolio in Q3 2025, its #927 holding.
  • Binnacle Investments first reported a position in Iovance Biotherapeutics in Q1 2025 and has held it in 2 quarters since.
  • Binnacle Investments's Iovance Biotherapeutics position peaked at $127 in Q1 2025.
  • 253 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2025.

Based on Binnacle Investments's 13F filing for Q3 2025, filed 14 Nov 2025.